Tokyo Tape
Sign in
← Medinet

Annual report

2370.TEDINET S100XB0H
Period2024-10-01 → 2025-09-30
Filed2025-12-17
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 83
MetricValuePeriodScopeSource row
Revenue¥810m2024-10-01 → 2025-09-30StandaloneNet sales
Revenue¥769m2023-10-01 → 2024-09-30StandaloneNet sales
Revenue¥662m2022-10-01 → 2023-09-30vStandaloneNet sales (5-year summary)
Revenue¥634m2021-10-01 → 2022-09-30vStandaloneNet sales (5-year summary)
Revenue¥683m2020-10-01 → 2021-09-30dStandaloneNet sales (5-year summary)
Operating income−¥1.4bn2024-10-01 → 2025-09-30StandaloneOperating income
Operating income−¥1.4bn2023-10-01 → 2024-09-30StandaloneOperating income
Ordinary income−¥1.3bn2024-10-01 → 2025-09-30StandaloneOrdinary income
Ordinary income−¥1.3bn2023-10-01 → 2024-09-30StandaloneOrdinary income
Ordinary income−¥1.4bn2022-10-01 → 2023-09-30vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.3bn2021-10-01 → 2022-09-30vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥871m2020-10-01 → 2021-09-30dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.4bn2024-10-01 → 2025-09-30StandaloneIncome before income taxes
Profit before tax−¥1.3bn2023-10-01 → 2024-09-30StandaloneIncome before income taxes
Net income−¥1.4bn2024-10-01 → 2025-09-30StandaloneProfit loss
Net income−¥1.3bn2023-10-01 → 2024-09-30StandaloneProfit loss
Net income−¥1.4bn2022-10-01 → 2023-09-30vStandaloneNet income loss (5-year summary)
Net income−¥1.3bn2021-10-01 → 2022-09-30vStandaloneNet income loss (5-year summary)
Net income−¥843m2020-10-01 → 2021-09-30dStandaloneNet income loss (5-year summary)
Total assets¥4.3bnat 2025-09-30StandaloneAssets
Total assets¥5.7bnat 2024-09-30StandaloneAssets
Total assets¥5.6bnat 2023-09-30vStandaloneTotal assets (5-year summary)
Total assets¥6.1bnat 2022-09-30vStandaloneTotal assets (5-year summary)
Total assets¥5.4bnat 2021-09-30dStandaloneTotal assets (5-year summary)
Total liabilities¥476mat 2025-09-30StandaloneLiabilities
Total liabilities¥509mat 2024-09-30StandaloneLiabilities
Net assets / equity¥3.8bnat 2025-09-30StandaloneNet assets
Net assets / equity¥5.2bnat 2024-09-30StandaloneNet assets
Net assets / equity¥5.0bnat 2023-09-30vStandaloneNet assets
Net assets / equity¥5.5bnat 2022-09-30vStandaloneNet assets (5-year summary)
Net assets / equity¥4.9bnat 2021-09-30dStandaloneNet assets (5-year summary)
Cash and deposits¥2.2bnat 2025-09-30StandaloneCash and deposits
Cash and deposits¥4.7bnat 2024-09-30StandaloneCash and deposits
Cash & equivalents¥2.7bnat 2025-09-30StandaloneCash and cash equivalents
Cash & equivalents¥4.7bnat 2024-09-30StandaloneCash and cash equivalents
Cash & equivalents¥4.4bnat 2023-09-30vStandaloneCash and cash equivalents
Cash & equivalents¥4.5bnat 2022-09-30vStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥4.1bnat 2021-09-30dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.4bn2024-10-01 → 2025-09-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.3bn2023-10-01 → 2024-09-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.3bn2022-10-01 → 2023-09-30vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.2bn2021-10-01 → 2022-09-30vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥975m2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥565m2024-10-01 → 2025-09-30StandaloneNet cash provided by used in investment activities
Investing cash flow¥65m2023-10-01 → 2024-09-30StandaloneNet cash provided by used in investment activities
Investing cash flow¥3m2022-10-01 → 2023-09-30vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥20m2021-10-01 → 2022-09-30vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥344m2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow−¥3m2024-10-01 → 2025-09-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.5bn2023-10-01 → 2024-09-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.2bn2022-10-01 → 2023-09-30vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.6bn2021-10-01 → 2022-09-30vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.1bn2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-5.152024-10-01 → 2025-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-5.042023-10-01 → 2024-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.652022-10-01 → 2023-09-30vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.332021-10-01 → 2022-09-30vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-4.882020-10-01 → 2021-09-30dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥14.27at 2025-09-30StandaloneNet assets per share (5-year summary)
Net assets per share¥19.62at 2024-09-30StandaloneNet assets per share (5-year summary)
Net assets per share¥21.64at 2023-09-30vStandaloneNet assets per share (5-year summary)
Net assets per share¥26.03at 2022-09-30vStandaloneNet assets per share (5-year summary)
Net assets per share¥27.31at 2021-09-30dStandaloneNet assets per share (5-year summary)
Equity ratio88.8%at 2025-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio91.1%at 2024-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio89.2%at 2023-09-30vStandaloneEquity to asset ratio (5-year summary)
Equity ratio90.7%at 2022-09-30vStandaloneEquity to asset ratio (5-year summary)
Equity ratio90.8%at 2021-09-30dStandaloneEquity to asset ratio (5-year summary)
ROE-30.4%2024-10-01 → 2025-09-30StandaloneRate of return on equity (5-year summary)
ROE-25.0%2023-10-01 → 2024-09-30StandaloneRate of return on equity (5-year summary)
ROE-27.3%2022-10-01 → 2023-09-30vStandaloneRate of return on equity (5-year summary)
ROE-24.1%2021-10-01 → 2022-09-30vStandaloneRate of return on equity (5-year summary)
ROE-17.5%2020-10-01 → 2021-09-30dStandaloneRate of return on equity (5-year summary)
Shares issued264,729,198at 2025-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued264,515,306at 2024-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued232,160,757at 2023-09-30vStandaloneTotal number of issued shares (5-year summary)
Shares issued211,730,423at 2022-09-30vStandaloneTotal number of issued shares (5-year summary)
Shares issued178,750,423at 2021-09-30dStandaloneTotal number of issued shares (5-year summary)
Employees107at 2025-09-30StandaloneNumber of employees
Employees112at 2024-09-30StandaloneNumber of employees
Employees98at 2023-09-30vStandaloneNumber of employees
Employees96at 2022-09-30vStandaloneNumber of employees
Employees83at 2021-09-30dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2024-10-01 → 2025-09-30¥4m
Reconciling Itemsreconcilingdepreciation2024-10-01 → 2025-09-30¥15m
Reconciling Itemsreconcilingsegment assetsat 2025-09-30¥3.4bn
Reconciling Itemsreconcilingsegment profit2024-10-01 → 2025-09-30−¥563m
Cellular And Tissue Based Product Businessreportable segmentcapex2024-10-01 → 2025-09-30¥3m
Cellular And Tissue Based Product Businessreportable segmentdepreciation2024-10-01 → 2025-09-30¥22m
Cellular And Tissue Based Product Businessreportable segmentemployeesat 2025-09-3016 pure
Cellular And Tissue Based Product Businessreportable segmentrevenue2024-10-01 → 2025-09-30¥219,000
Cellular And Tissue Based Product Businessreportable segmentrevenue external2024-10-01 → 2025-09-30¥219,000
Cellular And Tissue Based Product Businessreportable segmentsegment assetsat 2025-09-30¥139m
Cellular And Tissue Based Product Businessreportable segmentsegment profit2024-10-01 → 2025-09-30−¥408m
Contracted Cell Manufacturing Businessreportable segmentcapex2024-10-01 → 2025-09-30¥20m
Contracted Cell Manufacturing Businessreportable segmentdepreciation2024-10-01 → 2025-09-30¥64m
Contracted Cell Manufacturing Businessreportable segmentemployeesat 2025-09-3078 pure
Contracted Cell Manufacturing Businessreportable segmentrevenue2024-10-01 → 2025-09-30¥810m
Contracted Cell Manufacturing Businessreportable segmentrevenue external2024-10-01 → 2025-09-30¥810m
Contracted Cell Manufacturing Businessreportable segmentsegment assetsat 2025-09-30¥687m
Contracted Cell Manufacturing Businessreportable segmentsegment profit2024-10-01 → 2025-09-30−¥475m
—segment totalcapex2024-10-01 → 2025-09-30¥24m
—segment totaldepreciation2024-10-01 → 2025-09-30¥86m
—segment totalrevenue2024-10-01 → 2025-09-30¥810m
—segment totalrevenue external2024-10-01 → 2025-09-30¥810m
—segment totalsegment assetsat 2025-09-30¥826m
—segment totalsegment profit2024-10-01 → 2025-09-30−¥883m
Reconciling Itemsreconcilingcapex2023-10-01 → 2024-09-30¥2m
Reconciling Itemsreconcilingdepreciation2023-10-01 → 2024-09-30¥18m
Reconciling Itemsreconcilingsegment assetsat 2024-09-30¥4.9bn
Reconciling Itemsreconcilingsegment profit2023-10-01 → 2024-09-30−¥577m
Cellular And Tissue Based Product Businessreportable segmentcapex2023-10-01 → 2024-09-30¥21m
Cellular And Tissue Based Product Businessreportable segmentdepreciation2023-10-01 → 2024-09-30¥36m
Cellular And Tissue Based Product Businessreportable segmentrevenue2023-10-01 → 2024-09-30¥245,000
Cellular And Tissue Based Product Businessreportable segmentrevenue external2023-10-01 → 2024-09-30¥245,000
Cellular And Tissue Based Product Businessreportable segmentsegment assetsat 2024-09-30¥116m
Cellular And Tissue Based Product Businessreportable segmentsegment profit2023-10-01 → 2024-09-30−¥435m
Contracted Cell Manufacturing Businessreportable segmentcapex2023-10-01 → 2024-09-30¥23m
Contracted Cell Manufacturing Businessreportable segmentdepreciation2023-10-01 → 2024-09-30¥61m
Contracted Cell Manufacturing Businessreportable segmentrevenue2023-10-01 → 2024-09-30¥768m
Contracted Cell Manufacturing Businessreportable segmentrevenue external2023-10-01 → 2024-09-30¥768m
Contracted Cell Manufacturing Businessreportable segmentsegment assetsat 2024-09-30¥667m
Contracted Cell Manufacturing Businessreportable segmentsegment profit2023-10-01 → 2024-09-30−¥374m
—segment totalcapex2023-10-01 → 2024-09-30¥44m
—segment totaldepreciation2023-10-01 → 2024-09-30¥97m
—segment totalrevenue2023-10-01 → 2024-09-30¥769m
—segment totalrevenue external2023-10-01 → 2024-09-30¥769m
—segment totalsegment assetsat 2024-09-30¥783m
—segment totalsegment profit2023-10-01 → 2024-09-30−¥808m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 961
ItemContextValueUnit
Shareholding ratioCurrentYearInstant_No7MajorShareholdersMember0.0049
Number of shares heldCurrentYearInstant_No8MajorShareholdersMember1206900
Shareholding ratioCurrentYearInstant_No8MajorShareholdersMember0.0045
Number of shares heldCurrentYearInstant_No9MajorShareholdersMember1200000
Shareholding ratioCurrentYearInstant_No9MajorShareholdersMember0.0045
Number of shares heldCurrentYearInstant_No10MajorShareholdersMember1081700
Shareholding ratioCurrentYearInstant_No10MajorShareholdersMember0.0040
Number of shares heldCurrentYearInstant28133089
Shareholding ratioCurrentYearInstant0.1062
Number of shares issued shares voting rightsCurrentYearInstant_SharesWithNoVotingRightsMember－
Number of shares issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember－
Number of shares issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember－
Number of voting rights issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember－
Number of shares issued shares voting rightsCurrentYearInstant_SharesWithFullVotingRightsTreasurySharesEtcMember－
Number of shares issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember264703500
Number of voting rights issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember2647035
Number of shares issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember25698
Number of shares issued shares voting rightsCurrentYearInstant264729198
Number of voting rights issued shares voting rightsCurrentYearInstant2647035
Number of shares held in own name treasury shares etcCurrentYearInstant_Row1Member－
Number of shares held in others names treasury shares etcCurrentYearInstant_Row1Member－
Total number of shares held treasury shares etcCurrentYearInstant_Row1Member－
Shareholding ratio treasury shares etcCurrentYearInstant_Row1Member－
Number of shares held in own name treasury shares etcCurrentYearInstant－
Number of shares held in others names treasury shares etcCurrentYearInstant－
Total number of shares held treasury shares etcCurrentYearInstant－
Shareholding ratio treasury shares etcCurrentYearInstant－
Number of male directors and other officersFilingDateInstant10
Number of female directors and other officersFilingDateInstant－
Ratio of female directors and other officersFilingDateInstant－
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000KubushiroKanenaoMember172378
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000KimuraYoshijiMember7884922
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000OchiaiMasamiMember241458
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000KondoTakashigeMember236258
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000ShinodaTakeshiMember245753
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000YoshinoKoichiroMember119153
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000IchikawaKunihideMember53653
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000KotaroFuruichiMember－
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000KatayamaTakuroMember－
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000HasegawaAkihikoMember－
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant8953575
Audit fees reporting companyPrior1YearDuration17500000JPY
Non audit fees reporting companyPrior1YearDuration－JPY
Audit fees reporting companyCurrentYearDuration18000000JPY
Non audit fees reporting companyCurrentYearDuration－JPY
Total amount of remuneration etc remuneration etc by category of directors and other officersCurrentYearDuration_DirectorsExcludingOutsideDirectorsMember71858000JPY
Fixed remuneration remuneration by category of directors and other officersCurrentYearDuration_DirectorsExcludingOutsideDirectorsMember65575000JPY
Non monetary remuneration remuneration by category of directors and other officersCurrentYearDuration_DirectorsExcludingOutsideDirectorsMember6283000JPY
Number of directors and other officers remuneration etc by category of directors and other officersCurrentYearDuration_DirectorsExcludingOutsideDirectorsMember4
Total amount of remuneration etc remuneration etc by category of directors and other officersCurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2024-09-30pass rounding
balance sheet identitynon_consolidated 2025-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-09-30pass
statement vs summary · net assetsnon_consolidated 2024-09-30pass
statement vs summary · net assetsnon_consolidated 2025-09-30pass
statement vs summary · operating cash flownon_consolidated 2023-10-01/2024-09-30pass
statement vs summary · operating cash flownon_consolidated 2024-10-01/2025-09-30pass
statement vs summary · revenuenon_consolidated 2023-10-01/2024-09-30pass
statement vs summary · revenuenon_consolidated 2024-10-01/2025-09-30pass
statement vs summary · total assetsnon_consolidated 2024-09-30pass
statement vs summary · total assetsnon_consolidated 2025-09-30pass